Skip to main content

Advertisement

SpringerLink
Log in

Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition

  • Neuro-oncology (Y Umemura, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review highlights the spectrum of neurologic adverse events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the treatments undertaken, and the clinical outcomes.

Recent Findings

The advent of ICIs has revolutionized cancer therapy. Neurologic adverse events (NAEs) are rare but clinically significant complication of ICIs. They can involve both the central and peripheral nervous system. Examples include myositis, neuropathy, encephalopathy, and myasthenia gravis. Treatment consists of holding the ICI, administration of corticosteroids, and other immunomodulatory agents as needed. The outcomes are generally favorable; however, rarely severe events can lead to significant morbidity and even mortality.

Summary

Identifying and treating the range of neurologic adverse events that may potentially arise with ICIs is very important as the oncologic indications for their use continues to expand.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.

    Article  CAS  PubMed  Google Scholar 

  3. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.

    Article  CAS  PubMed  Google Scholar 

  6. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.

    Article  CAS  PubMed  Google Scholar 

  9. Eltobgy M, Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, et al. Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Neurother. 2017;17(7):725–36.

    Article  CAS  PubMed  Google Scholar 

  10. Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and Ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol. 2016;17(12):e529–41.

    Article  PubMed  Google Scholar 

  12. Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014 Sep;344(1–2):229–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lanfranchi M, Lee EQ, Buchbinder E, DeWitt J, Mehan WA. Pembrolizumab-related neuroinflammation: a case report and review of the literature. Neurographics. 2018;8(2):119–23.

    Article  Google Scholar 

  14. Jenkins MK. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165(2):302–19.

    Article  CAS  PubMed  Google Scholar 

  15. Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017;13(12):755–63.

    Article  CAS  PubMed  Google Scholar 

  16. Gibson HM, Hedgcock CJ, Aufiero BM, Wilson AJ, Hafner MS, Tsokos GC, et al. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007;179(6):3831–40.

    Article  CAS  PubMed  Google Scholar 

  17. Zheng Y, Josefowicz SZ, Kas A, Chu T-T, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445(7130):936–40.

    Article  CAS  PubMed  Google Scholar 

  18. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord [Internet]. 2018 [cited 2019 Jun 21];11. Available from: http://journals.sagepub.com/doi/10.1177/1756286418799864.

  21. Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016;78(1):119–22.

    PubMed  PubMed Central  Google Scholar 

  22. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2(1):35.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–40.

    Article  PubMed  Google Scholar 

  24. Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71–4.

    Article  PubMed  Google Scholar 

  25. Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, et al. Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol. 2016;11(9):1511–21.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncol. 2019. Aug 22. https://doi.org/10.1001/jamaoncol.2019.3221.

    Article  PubMed  PubMed Central  Google Scholar 

  27. •• Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462–9. Recent elegant analysis into the factors underlying responsiveness to checkpoint inhibition in glioblastoma.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Australian Pancreatic Cancer Genome Initiative, Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512–6.

    Article  PubMed Central  CAS  Google Scholar 

  31. Weiss MD, Luciano CA, Semino-Mora C, Dalakas MC, Quarles RH. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology. 1998;51(6):1738–41.

    Article  CAS  PubMed  Google Scholar 

  32. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst. 1987;78(1):45–54.

    Article  CAS  PubMed  Google Scholar 

  33. Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, Junker A, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis: CTLA4 and MS. Ann Neurol. 2016;80(2):294–300.

    Article  PubMed  PubMed Central  Google Scholar 

  34. •• Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology. 2017;74(10):1216. One of the largest retrospective cohorts of NAEs from the Mayo Clinic.

    Article  PubMed  PubMed Central  Google Scholar 

  35. •• Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8. One of the largest reviews of NAEs previously reported in case reports and series.

    Article  CAS  PubMed  Google Scholar 

  36. •• Spain L, Walls G, Julve M, O’Meara K, Schmid T, Kalaitzaki E, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol [Internet]. 2016 Oct 25 [cited 2018 Nov 20]; Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdw558. Large single-center retrospective cohort of NAEs from the Royal Marsden Hospital.

  37. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–54.

    Article  CAS  PubMed  Google Scholar 

  38. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Investig New Drugs. 2015;33(4):881–9.

    Article  CAS  Google Scholar 

  40. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.

    Article  CAS  PubMed  Google Scholar 

  42. Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol. 2018;2:25(5).

    Google Scholar 

  43. Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S, et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and Ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med. 2014;2014:1–6.

    Google Scholar 

  44. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and Ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013;1(2):92–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Current Neurology and Neuroscience Reports. 2018;18(10).

  46. Conry RM, Sullivan JC, Nabors LB. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res. 2015;3(6):598–601.

    Article  PubMed  Google Scholar 

  47. Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;bcr2016215012.

  48. Zurko J, Mehta A. Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):74–7.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Vitt JR, Kreple C, Mahmood N, Dickerson E, Lopez GY, Richie MB. Autoimmune pancerebellitis associated with pembrolizumab therapy. Neurology. 2018;91(2):91–3.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Williams TJ, Benavides DR, Patrice K-A, Dalmau JO, de Ávila ALR, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928.

    Article  PubMed  Google Scholar 

  51. Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep. 2018;18(1).

  53. Brown MP, Hissaria P, Hsieh AH, Kneebone C, Vallat W. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol. 2017;305:16–8.

    Article  CAS  PubMed  Google Scholar 

  54. Roberts P, Fishman GA, Joshi K, Jampol LM. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134(10):1184–8.

    Article  PubMed  Google Scholar 

  55. Maurice C, Schneider R, Kiehl T-R, Bavi P, Roehrl MHA, Mason WP, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunology Research. 2015;3(12):1299–302.

    Article  CAS  PubMed  Google Scholar 

  56. Cao Y, Nylander A, Ramanan S, Goods BA, Ponath G, Zabad R, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016;86(16):1553–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler J. 2015;21(5):670.

    Article  Google Scholar 

  58. Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer. 2016;4(1).

  59. Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol. 2015;35(2):144–7.

    Article  PubMed  Google Scholar 

  60. Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunology Research. 2016;4(3):175–8.

    Article  PubMed  Google Scholar 

  61. Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. Journal for ImmunoTherapy of Cancer. 2017;5(1).

  62. Dunn-Pirio AM, Shah S, Eckstein C. Neurosarcoidosis following immune checkpoint inhibition. Case Rep Oncol. 2018;27:521–6.

    Article  Google Scholar 

  63. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16(4):589–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. O’Kane GM, Lyons TG, Colleran GC, Ahmad MW, Alken S, Kavanagh EC, et al. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat. 2014;37(12):757–60.

    Article  PubMed  CAS  Google Scholar 

  65. Bompaire F, Mateus C, Taillia H, De Greslan T, Lahutte M, Sallansonnet-Froment M, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30(6):2407–10.

    Article  Google Scholar 

  66. de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375(3):296–7.

    Article  PubMed  Google Scholar 

  67. •• Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol. 2019;130(8):1440–5. Large and detailed study focusing on ICI-related neuropath and its electrophysiologic correlates.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry. 2018;89(4):435–7.

    Article  PubMed  Google Scholar 

  69. Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-Gonzalez S, Prat A, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2016;28(2):433–4.

    Article  Google Scholar 

  70. Altman AL, Golub JS, Pensak ML, Samy RN. Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngol Head Neck Surg. 2015;153(5):894–5.

    Article  PubMed  Google Scholar 

  71. Ali S, Lee S-K. Ipilimumab therapy for melanoma: a mimic of leptomeningeal metastases. Am J Neuroradiol. 2015;36(12):E69–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019;93(11):e1093–103.

    Article  CAS  PubMed  Google Scholar 

  73. Manousakis G, Koch J, Sommerville RB, El-Dokla A, Harms MB, Al-Lozi MT, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma: ipilimumab radiculoneuropathy. Muscle Nerve. 2013;48(3):440–4.

    Article  CAS  PubMed  Google Scholar 

  74. Jinnur P, Lim KG. Severe acute orthopnea: ipilimumab-induced bilateral phrenic nerve neuropathy. Lung. 2015;193(4):611–3.

    Article  PubMed  Google Scholar 

  75. Supakornnumporn S, Katirji B. Guillain–Barre’ syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis. 2017;19(2):4.

    Article  Google Scholar 

  76. Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S. A case of fatal Guillain–Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol. 2016;142(8):1869–70.

    Article  PubMed  Google Scholar 

  77. Gaudy-Marqueste C, Monestier S, Franques J, Richard M-A, Grob J-J. A severe case of ipilimumab-induced Guillain-Barre’ syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36(1):77–8.

    Article  PubMed  Google Scholar 

  78. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–3.

    Article  CAS  PubMed  Google Scholar 

  79. Hottinger AF. Neurologic complications of immune checkpoint inhibitors: current opinion in neurology. Curr Opin Neurol. 2016;29(6):806–12.

    Article  CAS  PubMed  Google Scholar 

  80. Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018;58(1):10–22.

    Article  Google Scholar 

  81. Green KE, Levine AM, Ward JH, Kaufman DI. GQ1b-Seronegative miller fisher syndrome associated with pembrolizumab. J Neuroophthalmol. 2019;39(3):394–6.

    Article  PubMed  Google Scholar 

  82. Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, et al. Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management. Am J Otolaryngol. 2018;39(5):642–5.

    Article  PubMed  Google Scholar 

  83. Huh S-Y, Shin S-H, Kim MK, Lee S-Y, Son KH, Shin HY. Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J Clin Neurol. 2018;14(1):115–7.

    Article  PubMed  Google Scholar 

  84. Chen Y-H, Liu F-C, Hsu C-H, Chian C-F. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine. 2017;96(27):e7350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Chen J-H, Lee K-Y, Hu C-J, Chung C-C. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine. 2017;96(50):e9262.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer: pembrolizumab-induced myasthenia gravis. Respirology Case Reports. 2018;6(7):e00355.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Mehta JJ, Maloney E, Srinivasan S, Seitz P, Cannon M. Myasthenia gravis induced by nivolumab: a case report. Cureus. 2017;20.

  88. Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46(1):86–8.

    Article  PubMed  Google Scholar 

  89. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–36.

    Article  CAS  PubMed  Google Scholar 

  93. Algaeed M, Mukharesh L, Heinzelmann M, Kaminski HJ. Pearls & Oy-sters: pembrolizumab-induced myasthenia gravis. Neurology. 2018;91(14):e1365–7.

    Article  PubMed  Google Scholar 

  94. Tan RYC, Toh CK, Takano A. Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis. J Thorac Oncol. 2017;12(7):e90–1.

    Article  PubMed  Google Scholar 

  95. Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27(3):266–8.

    Article  PubMed  Google Scholar 

  96. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu S-M, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer. 2016;4(1).

  97. Haddox CL, Shenoy N, Kao JC, Shah KK, Jain S, Halfdanarson TR, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol [Internet]. 2016 [cited 2018 Nov 21]; Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdw655.

  98. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74.

    Article  CAS  PubMed  Google Scholar 

  99. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68.

    Article  CAS  PubMed  Google Scholar 

  100. Schneider S, Potthast S, Komminoth P, Schwegler G, Böhm S. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017;10(2):473–8.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Bossart S, Thurneysen S, Rushing E, Frontzek K, Leske H, Mihic-Probst D, et al. Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist. 2017;22(6):749–53.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Leitinger M, Varosanec MV, Pikija S, Wass RE, Bandke D, Weis S, et al. Fatal necrotizing encephalopathy after treatment with Nivolumab for squamous non-small cell lung cancer: case report and review of the literature. Front Immunol. 2018;30:9.

    Google Scholar 

  103. Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Johnson DB, Saranga-Perry V, Lavin PJM, Burnette WB, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33(33):e122–4.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neuro-Oncology, Columbia University Irving Medical Center, 710 W 168th St, 9th Floor, New York, NY, 10032, USA

    Peter Chei-way Pan & Aya Haggiagi

Authors
  1. Peter Chei-way Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aya Haggiagi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aya Haggiagi.

Ethics declarations

Conflict of Interest

Peter Chei-way Pan and Aya Haggiagi declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pan, P.Cw., Haggiagi, A. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. Curr Oncol Rep 21, 108 (2019). https://doi.org/10.1007/s11912-019-0859-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0859-2

Keywords

Search

Navigation